Recombinant protein antigen for COVID-19 vaccine will be producing close to Lodz
MABION ANNOUNCES COMMERCIAL MANUFACTURING AGREEMENT FOR NOVAVAX COVID-19 VACCINE
October 8, 2021, in Konstantynów Łódzki (6km long way from LCJ), Mabion S.A. (WSE: MAB), a biotechnology company headquartered in Poland, announced the signing of a contract manufacturing agreement with Novavax for the large-scale production of the protein antigen used in Novavax’ recombinant nanoparticle protein-based COVID‑19 vaccine candidate, NVX-CoV2373. The four-year deal provides production capacity at Mabion’s Poland-based facility through 2026.
Antigen produced by Mabion will be integrated into Novavax’ global supply chain, which currently includes antigen production at sites across North America, Europe, India and Asia. In August, Novavax announced an advance purchase agreement with the European Commission for the purchase of up to 200 million doses of the Novavax COVID-19 vaccine.
Whole article: https://bit.ly/3DDx3ky
#covid19 #vaccine #Lodz #business #cargo